Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 451,122
  • Shares Outstanding, K 265,366
  • Annual Sales, $ 160,180 K
  • Annual Income, $ -69,410 K
  • EBIT $ 18 M
  • EBITDA $ 59 M
  • 60-Month Beta 0.31
  • Price/Sales 2.73
  • Price/Cash Flow N/A
  • Price/Book 10.52

Options Overview Details

View History
  • Implied Volatility 159.75% (-19.18%)
  • Historical Volatility 51.83%
  • IV Percentile 92%
  • IV Rank 37.35%
  • IV High 338.54% on 11/14/25
  • IV Low 53.15% on 01/23/25
  • Expected Move (DTE 21) 0.3230 (19.58%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 142
  • Volume Avg (30-Day) 296
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 46,587
  • Open Int (30-Day) 46,839
  • Expected Range 1.3270 to 1.9730

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.02
  • Number of Estimates 3
  • High Estimate 0.03
  • Low Estimate 0.01
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +120.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4450 +14.53%
on 12/02/25
1.7300 -4.34%
on 12/22/25
+0.0650 (+4.09%)
since 11/26/25
3-Month
1.4450 +14.53%
on 12/02/25
3.2000 -48.28%
on 10/28/25
-1.0850 (-39.60%)
since 09/26/25
52-Week
1.4450 +14.53%
on 12/02/25
4.0787 -59.42%
on 07/11/25
-0.2750 (-14.25%)
since 12/26/24

Most Recent Stories

More News
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?

Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you should play QTTB shares heading into 2026.

QTTB : 3.19 (-0.31%)
AKBA : 1.6550 (-2.65%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.6550 (-2.65%)
Q32 Bio Sells Complement Inhibitor ADX-097

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --

AKBA : 1.6550 (-2.65%)
QTTB : 3.19 (-0.31%)
Akebia Announces Establishment of Rare Kidney Disease Pipeline

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease...

AKBA : 1.6550 (-2.65%)
QTTB : 3.19 (-0.31%)
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.6550 (-2.65%)
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Vafseo ® (vadadustat) Q3 2025 net product revenues grew to  $14.3 million ; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete...

AKBA : 1.6550 (-2.65%)
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.6550 (-2.65%)
Akebia Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.6550 (-2.65%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.6550 (-2.65%)
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025,...

AKBA : 1.6550 (-2.65%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.7967
2nd Resistance Point 1.7533
1st Resistance Point 1.7267
Last Price 1.6550
1st Support Level 1.6567
2nd Support Level 1.6133
3rd Support Level 1.5867

See More

52-Week High 4.0787
Fibonacci 61.8% 3.0726
Fibonacci 50% 2.7619
Fibonacci 38.2% 2.4511
Last Price 1.6550
52-Week Low 1.4450

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar